Evaluation of per Vaginal Bleeding With Different Drugs in Successful Pregnancy in Patients With Recurrent Pregnancy Loss: An Original Research

J Pharm Bioallied Sci. 2022 Jul;14(Suppl 1):S193-S195. doi: 10.4103/jpbs.jpbs_90_22. Epub 2022 Jul 13.

Abstract

Introduction: One of the hormones that are crucial in safe pregnancy is the Progesterone. Its defect may cause bleeding and abortion. Hence, in this study, we evaluated two different drug modalities of progesterone for their efficacy.

Material and methods: We piloted a prospective observational study among 100 pregnant women in their first trimester. They were divided to two equal groups to receive oral dydrogesterone and vaginal progesterone. The clinical and the demographic data with detailed history were taken and noted. The patients were followed up till the pervaginal bleeding stopped and till second trimester end. The comparisons were made between the groups using Chi square test deliberating P < 0.05 as significant.

Results: The age, BMI, and the progesterone levels were comparable between the groups. No significant difference between the groups was seen for the adverse reactions and for the continuation of pregnancy till 24 weeks. However, there was a significant variation in the cessation of the pervaginal bleeding, with lower time for the oral dydrogesterone.

Conclusion: Compared to the vaginal progesterone, oral dydrogesterone performed better in preventing the pervaginal bleeding and prolonging the viability of the pregnancy till the second trimester end.

Keywords: Miscarriage; oral dydrogesterone; pervaginal bleeding; vaginal progesterone.